• 33141 Citations
  • 69 h-Index
19972019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Paolo Antonio Ascierto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 29 Similar Profiles
Melanoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Tumors Chemical Compounds
Mutation Medicine & Life Sciences
Safety Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1997 2019

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Cristiani, C. M., Turdo, A., Ventura, V., Apuzzo, T., Capone, M., Madonna, G., Mallardo, D., Garofalo, C., Giovannone, E. D., Grimaldi, A. M., Tallerico, R., Marcenaro, E., Pesce, S., Zotto, G. D., Agosti, V., Costanzo, F. S., Gulletta, E., Rizzo, A., Moretta, A., Karre, K. & 3 others, Ascierto, P. A., Todaro, M. & Carbone, E., May 2019, In : Cancer immunology research. 7, 5, p. 841-852 12 p.

Research output: Contribution to journalArticle

Natural Killer Cells
Melanoma
Galectins
Neoplastic Stem Cells
T-Lymphocyte Subsets

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., Sep 1 2019, In : European Journal of Cancer. 119, p. 1-10 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Survival
Neoplasm Metastasis
Recurrence
1 Citation (Scopus)

Adverse events 2.0—Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

Heinzerling, L., Ascierto, P. A., Dummer, R., Gogas, H., Grob, J. J., Lebbe, C., Long, G. V., McArthur, G., Moslehi, J. J., Neilan, T. G., Ribas, A., Robert, C., Schadendorf, D., Wolchok, J. D. & Hauschild, A., May 1 2019, In : European Journal of Cancer. 112, p. 29-31 3 p.

Research output: Contribution to journalLetter

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Sileni, V. C., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Gollerkeri, A., Pickard, M. D. & Robert, C., Sep 1 2019, In : European Journal of Cancer. 119, p. 97-106 10 p.

Research output: Contribution to journalArticle

Open Access
Cohort Studies
Mitogen-Activated Protein Kinase Kinases
Melanoma
encorafenib
MEK162
6 Citations (Scopus)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable

Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Russano, M., Anesi, C., Zeppola, T., Filetti, M. & 25 others, Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Rastelli, F., Pergolesi, F., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., De Giglio, A., Iacono, D., Gelibter, A., Occhipinti, M. A., Parisi, A., Porzio, G., Fargnoli, M. C., Ascierto, P. A., Ficorella, C. & Natoli, C., Feb 27 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 57.

Research output: Contribution to journalArticle

Open Access
Multicenter Studies
Body Mass Index
Neoplasms
Thinness
Renal Cell Carcinoma